BRG announced today that Rich Rieger has joined the firm's Health Analytics practice, where he will advise biopharmaceutical and MedTech companies on driving growth, performance improvement and ...

Monday was a grim day for a great many stocks, but luckily for its investors, AbbVie (NYSE: ABBV) wasn't one of them. The ...

AbbVie (NYSE:ABBV) continues to navigate the challenges of Humira's loss of exclusivity while leveraging its diverse portfolio and robust pipeline to drive future growth. With a gross profit margin of ...

Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceuticals and wellness company, today announced ...

AbbVie Inc. closed 15.68% short of its 52-week high of $207.32, which the company achieved on October 31st.

Wells Fargo analyst Mohit Bansal downgraded Vertex Pharmaceuticals (VRTX) to Equal Weight from Overweight with an unchanged price target of ...

AbbVie (ABBV) announced that it has completed its acquisition of Nimble Therapeutics. With the completion of the acquisition, Nimble is now a ...

AbbVie is one of the better pharmaceutical stocks on the scene, buttressed by a strong product lineup and a promising pipeline of developmental programs. It also pays quite a generous dividend ...

Let's decide whether AbbVie is a buy. In the pharmaceutical business, one home run can essentially build a company. AbbVie's success with Humira is a textbook example. Humira (adalimumab ...

Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceuticals and wellness company, today ...

The Sackler family, owners of Purdue Pharma, reached a $7.4 billion settlement to resolve mass opioid litigation. The Department of Justice filed a civil lawsuit against Walgreens over allegations it ...

Neomorph is building out its supply of Big Pharma partnerships, this time stamping down an option-to-license pact with AbbVie that centers around the biotech’s molecular glue platform. | Neomorph is ...